Genomic profiling to promote a healthy lifestyle: not ready for prime time (Q35201468)

7 August 2017

1 reference

title

Genomic profiling to promote a healthy lifestyle: not ready for prime time (English)

1 reference

7 August 2017

3

Wylie Burke

1 reference

7 August 2017

2

Muin J Khoury

1 reference

7 August 2017

Susanne B Haga

1

1 reference

PubMed ID

12923535

7 August 2017

language of work or name

English

0 references

publication date

1 August 2003

1 reference

7 August 2017

1 reference

7 August 2017

34

1 reference

7 August 2017

4

1 reference

7 August 2017

347-350

1 reference

https://scigraph.springernature.com/pub.10.1038/ng0803-347

7 August 2017

0 references

cites work

Shattuck lecture--medical and societal consequences of the Human Genome Project.

1 reference

https://api.crossref.org/works/10.1038%2FNG0803-347

7 January 2021

Pharmacogenetics and the practice of medicine

1 reference

https://api.crossref.org/works/10.1038%2FNG0803-347

7 January 2021

Replication validity of genetic association studies

1 reference

https://api.crossref.org/works/10.1038%2FNG0803-347

7 January 2021

A comprehensive review of genetic association studies

1 reference

https://api.crossref.org/works/10.1038%2FNG0803-347

7 January 2021

At the interfaces of epidemiology, genetics and genomics.

1 reference

https://api.crossref.org/works/10.1038%2FNG0803-347

7 January 2021

A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase

1 reference

https://api.crossref.org/works/10.1038%2FNG0803-347

7 January 2021

Mutated methylenetetrahydrofolate reductase as a risk factor for spina bifida

1 reference

https://api.crossref.org/works/10.1038%2FNG0803-347

7 January 2021

A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects?

1 reference

https://api.crossref.org/works/10.1038%2FNG0803-347

7 January 2021

Common mutation in methylenetetrahydrofolate reductase. Correlation with homocysteine metabolism and late-onset vascular disease.

1 reference

https://api.crossref.org/works/10.1038%2FNG0803-347

7 January 2021

Methylenetetrahydrofolate reductase gene and coronary artery disease

1 reference

https://api.crossref.org/works/10.1038%2FNG0803-347

7 January 2021

MTHFR 677C-->T polymorphism and risk of coronary heart disease: a meta-analysis.

1 reference

https://api.crossref.org/works/10.1038%2FNG0803-347

7 January 2021

Improving the prediction of complex diseases by testing for multiple disease-susceptibility genes

1 reference

https://api.crossref.org/works/10.1038%2FNG0803-347

7 January 2021

A Quantitative Assessment of Plasma Homocysteine as a Risk Factor for Vascular Disease

1 reference

https://api.crossref.org/works/10.1038%2FNG0803-347

7 January 2021

Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FNG0803-347

7 January 2021

Plasma homocysteine and risk for congestive heart failure in adults without prior myocardial infarction

1 reference

https://api.crossref.org/works/10.1038%2FNG0803-347

7 January 2021

Cancer prevention and diet: help from single nucleotide polymorphisms

1 reference

https://api.crossref.org/works/10.1038%2FNG0803-347

7 January 2021

Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance

1 reference

https://api.crossref.org/works/10.1038%2FNG0803-347

7 January 2021

Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus

1 reference

https://api.crossref.org/works/10.1038%2FNG0803-347

7 January 2021

Pharmacogenetics of cancer therapy: getting personal

1 reference

https://api.crossref.org/works/10.1038%2FNG0803-347

7 January 2021

Pharmacogenetics as a molecular basis for individualized drug therapy: the thiopurine S-methyltransferase paradigm

1 reference

https://api.crossref.org/works/10.1038%2FNG0803-347

7 January 2021

Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy

1 reference

https://api.crossref.org/works/10.1038%2FNG0803-347

7 January 2021

Genetic test evaluation: information needs of clinicians, policy makers, and the public

1 reference

https://api.crossref.org/works/10.1038%2FNG0803-347

7 January 2021

Genetic risk and behavioural change

1 reference

https://api.crossref.org/works/10.1038%2FNG0803-347

7 January 2021

Limitations of direct-to-consumer advertising for clinical genetic testing

1 reference

https://api.crossref.org/works/10.1038%2FNG0803-347

7 January 2021

Reporting, appraising, and integrating data on genotype prevalence and gene-disease associations

1 reference

https://api.crossref.org/works/10.1038%2FNG0803-347

7 January 2021

Phenotypes of patients with "simple" Mendelian disorders are complex traits: thresholds, modifiers, and systems dynamics

1 reference

https://api.crossref.org/works/10.1038%2FNG0803-347

7 January 2021

Discrepancies between genotype and phenotype in hematology: an important frontier

1 reference

https://api.crossref.org/works/10.1038%2FNG0803-347

7 January 2021

Finding genes that underlie complex traits

1 reference

https://api.crossref.org/works/10.1038%2FNG0803-347

7 January 2021

Identifiers

DOI

10.1038/NG0803-347

1 reference

7 August 2017

1 reference

PubMed ID

12923535